In another win for rival Aimmune, FDA presses pause on DBV's peanut patch with additional questions
Another regulatory setback has strayed DBV Therapeutics’s peanut allergy patch off the path to approval.
On Monday, the company disclosed that the FDA, which is …
Sign up to read this article for free.
Get free access to a limited number of articles, plus choose newsletters to get straight to your inbox.
